[Clinical value of OK-432 immunotherapy after one-shot arterial infusion of anti-cancer agents in the treatment of hepatocellular carcinoma--a randomized study].
Horie
Y
Y
2nd Dept. of Medicine, Tottori University School of Medicine.
Hirai
K
K
Shimizu
M
M
Inoue
J
J
Kubo
Y
Y
Hara
Y
Y
Tanikawa
K
K
Okumura
M
M
Hirayama
C
C
Ogawa
N
N
D000284:Administration, Oral; D001688:Biological Products / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage*; D010844:Picibanil / Q000627:therapeutic use*; D011897:Random Allocation; D005641:Tegafur / Q000008:administration & dosage
D001688:Biological Products; D008937:Mitomycins; D005641:Tegafur; D010844:Picibanil; D016685:Mitomycin